Hutchmed China Ltd on Tuesday said it has completed patient enrolment for a phase II registration trial of savolitinib, targeting gastric cancer in patients with MET gene amplification.
Shares in Hutchmed China were up 12% at 237.40 pence in London on Tuesday morning.
The Hong Kong-based biopharmaceutical firm said the trial, conducted in China, is evaluating the efficacy and safety of savolitinib in treating gastric or gastroesophageal junction adenocarcinoma patients with MET amplification, a condition estimated to affect 4% to 6% of gastric cancer patients and linked to poor prognosis. A total of 64 patients have been enrolled.
Interim results showed a 45% objective response rate overall, rising to 50% in patients with high MET gene copy numbers. The four-month duration of response rate was around 86%, with a median follow-up of 5.5 months.
China’s National Medical Products Administration has already granted the drug breakthrough therapy designation. If final results are positive, Hutchmed said it may file for marketing approval in late 2025.
Savolitinib, an oral MET tyrosine kinase inhibitor developed with AstraZeneca PLC, is already approved in China for a form of lung cancer under the brand name Orpathys. It is being studied for multiple cancer types.
Copyright 2025 Alliance News Ltd. All Rights Reserved.
